BCLI (BrainStorm Cell Therapeutics Inc.) Market Value to Book Value Ratio

Official company branding of Brainstorm Cell Therapeutics Inc. (BCLI)

Optimized chilled biomaterial delivery chains ensure the seamless operation of Brainstorm Cell. Brainstorm Cell is developing robust R&D capabilities in neuroscience, creating the NurOwn platform for ALS therapy. The team, led by Haim Lebovitz, strives for medical breakthroughs in the treatment of degeneration. This chart of the market cap to book value ratio demonstrates market expectations, where the value of -1.24 reflects the metric's balance.

BCLI - brainstorm-cell.com Market-to-Book Ratio over the range 07/04/2022 - 08/02/2025

Financial and market metric breakdowns for Brainstorm Cell Therapeutics Inc. (BCLI)

- price and consensus price forecast:
Stock Price Brainstorm Cell|BCLI - Analyst Median Target
- market capitalization data:
Market Value Brainstorm Cell|BCLI - Business Value
- book capitalization data:
Book Value per Share BrainStorm Cell Therapeutics|BCLI - Total Stockholders' Equity|Market Cap to Net Assets Ratio brainstorm-cell.com|BCLI - Company Total Assets
- debt and liquidity data:
Debt to Equity Brainstorm Cell|BCLI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Brainstorm Cell Therapeutics, Inc.|BCLI - Company Cumulative Debt|Debts to Book Capitalization Brainstorm Cell
Initial company analysis:Brainstorm Cell
Original product of Brainstorm Cell Therapeutics, Inc.

This indicator compares the market value of Brainstorm Cell (BCLI) with its actual net assets, reflecting investor market expectations. In the case of Brainstorm Cell (BCLI), the premium of market value over book capital is based on the commercialization potential of NurOwn therapy. A high asset premium indicates that the price currently prices in the value of future drug sales. However, such a discrepancy increases the risk of price volatility. Investors should assess this gap as a measure of speculative optimism.

Direct competitors

Biogen Inc. - Market Capitalization to Book Value Ratio|NBIX (neurocrine.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Amylyx Pharmaceuticals|Market Value to Book Value Ratio TRVI|Praxis Precision Medicines, Inc. (PRAX) - Market Value to Book Value Ratio|Market Value to Book Value Anavex (AVXL)|Market Capitalization to Book Value Ratio CBLL (CeriBell Corp)|Market Capitalization to Book Value Ratio Prothena PRTA|Market Capitalization to Book Value Ratio ALEC (Alector Therapeutics)|ANNX: Market Capitalization to Book Value|Market Value to Book Value Ratio omeros.com|NGNE (Neurogene Inc) - Capitalization to Book Value Ratio|ACIU: Market Value to Book Value Ratio|Market Capitalization to Book Value Voyager Corp (VYGR)|Market Cap to Net Assets Ratio Neumora Therapeutics|Market Cap to Book Value Multiple SCLX (scilexholding.com)|TVGN: Market Value to Book Value Ratio|Alpha Cognition Inc - Market-to-Book Ratio|Market Value to Book Value Ratio Cognition Therapeutics, Inc. (CGTX)|IKT: Market Value to Book Value|SAVA (Cassava Sciences, Inc.) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Assertio|COYA - Market Cap to Net Assets Ratio|Market Value to Book Value VistaGen Therapeutics Inc|Market Capitalization to Book Value Ratio OVID (Ovid Therapeutics Inc.)|Market Cap to Net Assets Ratio Acumen Pharmaceuticals, Inc (ABOS)|CRVO: Market Capitalization to Book Value Ratio|Alterity Therapeutics Ltd. - Market-to-Book Ratio|CLNN - Market Value to Book Value Ratio|PEPG: Market Value to Book Value Ratio|Jupiter Neurosciences (JUNS) - Market Value to Book Value Ratio|Relmada Corp (RLMD) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio Annovis Bio, Inc.|Market Value to Book Value Ratio Grace Tx|Market Capitalization to Book Value Ratio AIFF (Firefly Neuroscience)|Market Cap to Net Assets Ratio KLTO (anewmeds.com)|Market Value to Book Value Ratio NeuroSense Therapeutics Ltd. NRSN|Market Value to Book Value Ratio Reviva Pharmaceuticals, Inc. RVPH|Market Capitalization to Book Value Ratio MTVA (MetaVia, Inc.)|NRXS: Market Capitalization to Book Value|Market Value to Book Value Ratio heliusmedical.com|Passage Bio (PASG) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio NEUP (Neuphoria Therapeutics, Inc.)|Market-to-Book Ratio Minerva (NERV)|Market Cap to Net Assets Ratio ATHA|Market Capitalization to Book Value Ratio ADXN (addextherapeutics.com)|Market Value to Book Value Ratio Alzamend Neuro|Cyclerion Therapeutics Inc. - Market Value to Book Value|PTIX (Protagenic) - Market Value to Book Value Ratio|KTTA - Market-to-Book Ratio|cortigent.com (CRGT) - Market Capitalization to Book Value Ratio|ATXI (avenuetx.com) - Market Value to Book Value Ratio|CARA - Market Value to Book Value Ratio|Market Value to Book Value Chromocell Therapeutics Corp|Market Capitalization to Book Value Ratio ELYM|Market Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|Market Capitalization to Book Value Ratio LBPH|marinuspharma.com - Market Capitalization to Book Value|NKGen Biotech (NKGN) - Market Value to Book Value Ratio|NRBO: Capitalization to Book Value Ratio|Sage Therapeutics, Inc - Market Value to Book Value Ratio|Market Capitalization to Book Value Synaptogenix, Inc|Trevena, Inc. (TRVN) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple VIGL|Anew Medical, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio CERE (Cerevel Therapeutics Inc)